Stocks Health care CRDF
NASDAQ · Health careCardiff Oncology, Inc. (CRDF)
Cardiff Oncology, Inc. brought in $508K of revenue over the twelve months to June 30, 2026, down 6.8% from a year earlier. It posted a net loss of $40.1M. In fiscal 2025 capital spending exceeded operating cash flow by $38M. At June 30, 2026 it held $9.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.
Key facts about Cardiff Oncology, Inc.
- Net worth
- Cardiff Oncology, Inc. has a market value (market cap) of $61.8M at the latest share price, and shareholders' equity of $26.5M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $593K (-13.2% year on year), with a net loss of $45.9M. Over the 12 months to June 30, 2026: revenue $508K, net loss $40.1M.
- Cash flow
- In fiscal 2025 operations used $37.9M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 11, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Cardiff Oncology, Inc.'s next report was expected around November 5, 2026 and is not on file with the SEC yet.
What Cardiff Oncology, Inc. does
Cardiff Oncology, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker CRDF.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $593K | -$45.9M | -$0.69 | -$38M |
| 2024 | $683K | -$45.4M | -$0.95 | -$37.8M |
| 2023 | $488K | -$41.4M | -$0.93 | -$31.5M |
| 2022 | $386K | -$38.7M | -$0.89 | -$34.8M |
| 2021 | $359K | -$28.3M | -$0.73 | -$23.2M |
| 2020 | $366K | -$19.3M | -$1.08 | -$16.5M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where CRDF ranks in Health care
Latest SEC filings
What Cardiff Oncology, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 14, 2026
- August 26, 2026Additional proxy material DEFA14A
- August 26, 2026Proxy statement DEF 14A
- August 14, 2026Preliminary proxy statement PRE 14A
- August 11, 2026
- August 11, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 14% to $104K versus the same quarter last year; diluted EPS -$0.14 versus -$0.21.
- July 27, 2026Passive stake changed SCHEDULE 13G/A
- July 21, 2026
- July 16, 2026
- June 11, 2026
Insider trades
What the people running Cardiff Oncology, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| July 14, 2026 | Mohindru ManiChief Executive Officer, Director | Bought | 34,364 | $50K |
| July 14, 2026 | Pace Gary WDirector | Bought | 687,285 | $1M |
| June 18, 2026 | Pace Gary WDirector | Bought | 30,000 | $36.6K |
| June 18, 2026 | Mohindru ManiChief Executive Officer, Director | Bought | 24,703 | $29.9K |
Who owns CRDF
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
Largest institutional holders
Insiders
2 insiders reported holding 2,102,728 shares in total, about $1.7M at the last price.
| Holder | Shares |
|---|---|
| Pace Gary WDirector | 2,043,661 |
| Mohindru ManiChief Executive Officer, Director | 59,067 |
Questions about CRDF
What does Cardiff Oncology, Inc. do?
Cardiff Oncology, Inc. is a company in the Health care sector, listed on NASDAQ as CRDF. Its shares trade on NASDAQ under the ticker CRDF.
What is Cardiff Oncology, Inc.'s net worth?
Cardiff Oncology, Inc. has a market value (market cap) of $61.8M at the latest share price, and shareholders' equity of $26.5M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Cardiff Oncology, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $40.1M on revenue of $508K.
How much revenue does Cardiff Oncology, Inc. make?
Over the twelve months to June 30, 2026 Cardiff Oncology, Inc. reported revenue of $508K. That is 6.8% less than a year earlier.
When did Cardiff Oncology, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the material agreement from September 14, 2026.
When is Cardiff Oncology, Inc.'s next earnings report?
Cardiff Oncology, Inc.'s next report was expected around November 5, 2026 and is not on file with the SEC yet.
Similar companies
Compare CRDF with
Follow CRDF
Get an email when Cardiff Oncology, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Cardiff Oncology, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.